Gene Therapy for Achromatopsia (CNGA3)

Completed · Phase 1/Phase 2

Conditions studied: Achromatopsia

In brief

A clinical trial of adeno-associated virus vector (AAV) CNGA3 retinal gene therapy for patients with achromatopsia

Key facts

Study ID

NCT03758404

Run by

MeiraGTx UK II Ltd

People needed

11

Starts

2019-08-12

Expected to finish

2021-06-10

Last updated by the study team

2022-12-01

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are aged years or over
• Have achromatopsia confirmed by a retinal specialist investigator

You may not qualify if…

• Are females who are pregnant or breastfeeding
• Have participated in another research study involving an investigational medicinal therapy for ocular disease within the last 6 months
• Have any other condition that the investigator considers makes them inappropriate for entry into the trial

Where it is running

• Kellogg Eye Center — Ann Arbor, Michigan, United States
• Moorfields Eye Hospital NHS Foundation Trust — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.